Spectrum Pharmaceuticals Inc (SPPI)

6.66
0.15 2.30
NASDAQ : Health Care
Prev Close 6.51
Open 6.52
Day Low/High 6.47 / 6.63
52 Wk Low/High 4.14 / 7.74
Volume 12.49K
Avg Volume 817.40K
Exchange NASDAQ
Shares Outstanding 69.22M
Market Cap 447.86M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Spectrum Pharmaceuticals To Present Corporate Update At The Cantor Fitzgerald's 2nd Annual Healthcare Conference On July 13th

Spectrum Pharmaceuticals To Present Corporate Update At The Cantor Fitzgerald's 2nd Annual Healthcare Conference On July 13th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Spectrum Pharmaceuticals Enters Oversold Territory (SPPI)

Spectrum Pharmaceuticals Enters Oversold Territory (SPPI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of February 2017 Options Trading For Spectrum Pharmaceuticals (SPPI)

First Week of February 2017 Options Trading For Spectrum Pharmaceuticals (SPPI)

Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the February 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2016 Healthcare Conference On June 8th

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2016 Healthcare Conference On June 8th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Spectrum Pharmaceuticals Highlights An Oral Presentation On Apaziquone At The 2016 Annual Meeting Of The American Urological Association Education And Research Inc. (AUA) In San Diego, California, May 6-10, 2016

Spectrum Pharmaceuticals Highlights An Oral Presentation On Apaziquone At The 2016 Annual Meeting Of The American Urological Association Education And Research Inc. (AUA) In San Diego, California, May 6-10, 2016

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today presentations of clinical...

Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today financial results...

Spectrum Pharmaceuticals To Present Corporate Update At The Bank Of America Merrill Lynch 2016 Healthcare Conference On May 10th

Spectrum Pharmaceuticals To Present Corporate Update At The Bank Of America Merrill Lynch 2016 Healthcare Conference On May 10th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Spectrum Pharmaceuticals Announces First Quarter 2016 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces First Quarter 2016 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a...

FDA Grants Orphan Drug Exclusivity To EVOMELA™ (melphalan) For Injection, Indicated For Multiple Myeloma

FDA Grants Orphan Drug Exclusivity To EVOMELA™ (melphalan) For Injection, Indicated For Multiple Myeloma

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.

Spectrum Pharmaceuticals Stock Sees Short Interest Fall 12.5%

Spectrum Pharmaceuticals Stock Sees Short Interest Fall 12.5%

The most recent short interest data has been released by the NASDAQ for the 03/31/2016 settlement date, which shows a 1,419,694 share decrease in total short interest for Spectrum Pharmaceuticals Inc , to 9,973,793, a decrease of 12.46% since 03/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

First Week of November 18th Options Trading For Spectrum Pharmaceuticals (SPPI)

First Week of November 18th Options Trading For Spectrum Pharmaceuticals (SPPI)

Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the November 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

FDA Grants Spectrum Pharmaceuticals Approval Of EVOMELA™ (melphalan) For Injection

FDA Grants Spectrum Pharmaceuticals Approval Of EVOMELA™ (melphalan) For Injection

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.

Weak On High Volume: Spectrum Pharmaceuticals (SPPI)

Weak On High Volume: Spectrum Pharmaceuticals (SPPI)

Trade-Ideas LLC identified Spectrum Pharmaceuticals (SPPI) as a weak on high relative volume candidate

Spectrum Pharmaceuticals Reports Fourth Quarter 2015 And Full Year 2015 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports Fourth Quarter 2015 And Full Year 2015 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today financial results...

Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial For Poziotinib, A Novel Pan-HER Inhibitor

Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial For Poziotinib, A Novel Pan-HER Inhibitor

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the Company has...

Spectrum Pharmaceuticals Announces Fourth Quarter And Full Year 2015 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Fourth Quarter And Full Year 2015 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a...

Spectrum Pharmaceuticals To Present Corporate Update At 2016 RBC Capital Markets' Global Healthcare Conference On February 24

Spectrum Pharmaceuticals To Present Corporate Update At 2016 RBC Capital Markets' Global Healthcare Conference On February 24

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Spectrum Pharmaceuticals Announces FDA's Acceptance Of NDA Filing For EOquin® (apaziquone For Intravesical Instillation)

Spectrum Pharmaceuticals Announces FDA's Acceptance Of NDA Filing For EOquin® (apaziquone For Intravesical Instillation)

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced that the U.

Spectrum Pharmaceuticals Becomes Oversold (SPPI)

Spectrum Pharmaceuticals Becomes Oversold (SPPI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Weak On High Volume: Spectrum Pharmaceuticals (SPPI)

Weak On High Volume: Spectrum Pharmaceuticals (SPPI)

Trade-Ideas LLC identified Spectrum Pharmaceuticals (SPPI) as a weak on high relative volume candidate

Spectrum Pharmaceuticals Begins Enrolling Patients In Registrational Trial Of SPI-2012, A Novel, Long Acting G-CSF In Patients With Breast Cancer

Spectrum Pharmaceuticals Begins Enrolling Patients In Registrational Trial Of SPI-2012, A Novel, Long Acting G-CSF In Patients With Breast Cancer

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, announced today the Company has...

First Week of March 18th Options Trading For Spectrum Pharmaceuticals (SPPI)

First Week of March 18th Options Trading For Spectrum Pharmaceuticals (SPPI)

Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the March 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new March 18th contracts and identified one put and one call contract of particular interest.

Spectrum Pharmaceuticals Signs A Strategic Partnership With Servier Canada

Spectrum Pharmaceuticals Signs A Strategic Partnership With Servier Canada

Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology and Servier Canada Inc.

Spectrum Pharmaceuticals Announces Agreement With FDA On The Special Protocol Assessment (SPA) For The Registrational Trial Of SPI-2012, A Novel, Long Acting G-CSF In Patients With Breast Cancer

Spectrum Pharmaceuticals Announces Agreement With FDA On The Special Protocol Assessment (SPA) For The Registrational Trial Of SPI-2012, A Novel, Long Acting G-CSF In Patients With Breast Cancer

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations, and a primary focus in Hematology and Oncology, announced today that the company has...

TheGrantLawFirm, PLLC Withdraws Action on Behalf of Spectrum Pharmaceuticals, Inc. Purchasers

TheGrantLawFirm, PLLC Withdraws Action on Behalf of Spectrum Pharmaceuticals, Inc. Purchasers

On November 17, 2015, TheGrantLawFirm, PLLC disseminated a notice to shareholders under the PSLRA, announcing that it filed a class action complaint ("Complaint") on behalf of all securities holders who purchased securities...

Spectrum Pharmaceuticals, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Spectrum Pharmaceuticals, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...